COLL
Collegium Pharmaceutical, Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Collegium Pharmaceutical, Inc
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report3 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
No thesis.
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
−18.55%
vs ±12.2% implied · ×1.52
shaded = implied · ▲▼ = realized
Collegium Pharmaceutical, Inc
23.74
+0.06 · +0.27%
post 23.75 +0.03%
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Collegium Pharmaceutical, Inc's 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Collegium Pharmaceutical, Inc's 6 closest co-movers, none share that code.
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $197.0M | 13.88% | +5.98% |
| Jupiter Topco | $77.7M | 5.48% | — |
| Invesco | $68.1M | 4.80% | +18.25% |
| Fuller & Thaler | $59.1M | 4.16% | +8.88% |
| Principal Financial | $59.1M | 4.16% | +26.05% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $197.0M | 13.88% | +5.98% |
| Jupiter Topco | $77.7M | 5.48% | — |
| Invesco | $68.1M | 4.80% | +18.25% |
| Fuller & Thaler | $59.1M | 4.16% | +8.88% |
| Principal Financial | $59.1M | 4.16% | +26.05% |
Tall tick = annual report · Source: EDGAR
Largest filed tie
—
—
—
Bull1
Bear2
Expected move
Inputs8Q avg ±8.7%·×1.87·rich
straddle ±17.0%
spot 23.73exp Nov 20ATM strike 22.5ATM straddle 4.75IV 117%